ADC Therapeutics SA (ADCT) · Nov 4, 2026 · Other events
ASH data preview — Five oral presentations; LOTIS-5 PFS statistically significant
ADC Therapeutics previews ASH data across ZYNLONTA trials, adding breadth to the pipeline story while leaving the key FDA approval hurdle unresolved.
ADC Therapeutics is a commercial-stage biotech built around ZYNLONTA, trying to expand the drug beyond its existing late-line DLBCL use while revenue growth remains a 2027 objective. Earlier 2026 disclosures already established positive LOTIS-5 efficacy, completed LOTIS-7 enrollment, and a regulatory review complicated by FDA benefit-risk concerns.
The filing broadens the evidence package, but mostly confirms an expected milestone. ADC says five presentations, including oral LOTIS-7, marginal-zone lymphoma, and full LOTIS-5 results, will be presented at ASH on December 12–15. The direction was already anticipated because the company had submitted the abstracts and previously expected full LOTIS-5 and LOTIS-7 data by year-end.
LOTIS-5 provides useful confirmation, but not a clean regulatory win. The release says the 420-patient Phase 3 study produced a statistically significant improvement in progression-free survival versus R-GemOx. That supports the clinical-efficacy case, but the filing also flags “serious concerns” raised by the FDA at the recent pre-sBLA meeting, meaning the central question is now whether the benefit-risk profile is sufficient for full approval—not whether the trial hit its primary endpoint.
The earlier-line and new-indication story gets more credible, but remains preliminary. Updated LOTIS-7 data and MZL investigator-led data could support future compendia inclusion or regulatory work, and the company explicitly points to planned Phase 3 studies. But this filing provides no detailed response rates, durability figures, safety tables, or regulatory commitments for those programs, so it strengthens the breadth of the story without materially removing execution risk.
Bottom line: This is a modestly constructive ASH preview, not a major reset. It adds breadth and reinforces the efficacy narrative, but the unresolved FDA concerns keep the filing from converting that clinical promise into a clear regulatory advance.
ASH presentations, December 12–15, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!